AR027656A1 - Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa - Google Patents

Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa

Info

Publication number
AR027656A1
AR027656A1 ARP010101185A ARP010101185A AR027656A1 AR 027656 A1 AR027656 A1 AR 027656A1 AR P010101185 A ARP010101185 A AR P010101185A AR P010101185 A ARP010101185 A AR P010101185A AR 027656 A1 AR027656 A1 AR 027656A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
glucogeno
fosforilasa
inhibitors
polymer
Prior art date
Application number
ARP010101185A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR027656A1 publication Critical patent/AR027656A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Composiciones farmacéuticas que contienen un inhibidor de la glucogeno-fosforilasa y como mínimo un polímero que aumenta la concentracion. La composicionpuede ser una mezcla física simple de un inhibidor de la glucogeno-fosforilasa y un polímero que aumenta la concentracion, o una dispersion de un inhibidor dela glucogeno-fosforilasa y un polímero.
ARP010101185A 2000-03-16 2001-03-14 Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa AR027656A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
AR027656A1 true AR027656A1 (es) 2003-04-09

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101185A AR027656A1 (es) 2000-03-16 2001-03-14 Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa

Country Status (32)

Country Link
US (1) US20010053778A1 (es)
EP (1) EP1263414A1 (es)
JP (1) JP2003526654A (es)
KR (1) KR20020081445A (es)
CN (1) CN1418089A (es)
AP (1) AP2002002621A0 (es)
AR (1) AR027656A1 (es)
AU (1) AU2001242669A1 (es)
BG (1) BG107037A (es)
BR (1) BR0109189A (es)
CA (1) CA2403241A1 (es)
CO (1) CO5280087A1 (es)
CZ (1) CZ20022955A3 (es)
EA (1) EA200200858A1 (es)
EE (1) EE200200530A (es)
HU (1) HUP0204583A2 (es)
IL (1) IL151320A0 (es)
IS (1) IS6508A (es)
MA (1) MA26882A1 (es)
MX (1) MXPA02009097A (es)
NO (1) NO20024386L (es)
OA (1) OA12232A (es)
PA (1) PA8513601A1 (es)
PE (1) PE20011184A1 (es)
PL (1) PL360780A1 (es)
SK (1) SK12622002A3 (es)
SV (1) SV2002000343A (es)
TN (1) TNSN01040A1 (es)
TR (1) TR200202184T2 (es)
WO (1) WO2001068055A1 (es)
YU (1) YU67202A (es)
ZA (1) ZA200207290B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2002002552A0 (en) * 1999-12-23 2002-06-30 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations.
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
SK15742003A3 (sk) 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutická kompozícia zahrnujúca adsorbát amorfného liečiva
ES2333645T3 (es) * 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CA2472028C (en) 2002-02-01 2010-03-30 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
AU2003239463B2 (en) 2002-02-01 2007-10-18 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
MXPA04007438A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
CA2548376A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
ATE483708T1 (de) 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
KR102138545B1 (ko) * 2012-08-24 2020-07-28 다우 글로벌 테크놀로지스 엘엘씨 고분자량 및 높은 균일성을 갖는 신규한 에스테르화된 셀룰로즈 에테르
HUE057701T2 (hu) 2012-09-11 2022-05-28 Medivation Prostate Therapeutics Llc Enzalutamid kiszerelési formái
EP3763702B1 (en) 2013-07-19 2023-12-13 Siga Technologies, Inc. Preparation of amorphous tecovirimat dispersions
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0832065T3 (da) * 1995-06-06 2001-11-19 Pfizer Substituerede N-(indol-2-carbonyl)glycinamider og derivater som glycogenphosphorylaseinhibitorer
MX9709874A (es) * 1995-06-06 1998-03-31 Pfizer N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
JP2003526654A (ja) 2003-09-09
PL360780A1 (en) 2004-09-20
PA8513601A1 (es) 2004-08-31
WO2001068055A1 (en) 2001-09-20
NO20024386L (no) 2002-11-13
EE200200530A (et) 2004-04-15
BG107037A (bg) 2003-04-30
ZA200207290B (en) 2003-09-11
KR20020081445A (ko) 2002-10-26
IL151320A0 (en) 2003-04-10
PE20011184A1 (es) 2001-11-15
TNSN01040A1 (fr) 2005-11-10
IS6508A (is) 2002-08-16
CA2403241A1 (en) 2001-09-20
CN1418089A (zh) 2003-05-14
AP2002002621A0 (en) 2002-09-30
BR0109189A (pt) 2003-05-27
TR200202184T2 (tr) 2003-01-21
CO5280087A1 (es) 2003-05-30
EA200200858A1 (ru) 2003-02-27
SK12622002A3 (sk) 2004-02-03
EP1263414A1 (en) 2002-12-11
OA12232A (en) 2006-05-10
NO20024386D0 (no) 2002-09-13
AU2001242669A1 (en) 2001-09-24
US20010053778A1 (en) 2001-12-20
MXPA02009097A (es) 2003-03-12
HUP0204583A2 (hu) 2003-04-28
SV2002000343A (es) 2002-07-03
YU67202A (sh) 2006-01-16
MA26882A1 (fr) 2004-12-20
CZ20022955A3 (cs) 2003-09-17

Similar Documents

Publication Publication Date Title
AR027656A1 (es) Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
UY26864A1 (es) Composiciones farmaceúticas de inhibidores de la proteína de transferencia de colesteril éster
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
DK1515702T6 (da) Misbrugssikret indgivelsesform
SE0102315D0 (sv) Compounds
AR038207A1 (es) Composicion farmaceutica dispersable oralmente de agomelatina
HK1074592A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
PT1117440E (pt) Composicoes farmaceuticas que contem paclitaxel
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
ECSP024382A (es) Inhibidores de proteasa de serina
AR023641A1 (es) Una composicion de copolimeros de propileno cristalinos, un procedimiento para prepararla, y una pelicula o lamina monocapa o multicapa que comprende adicha composicion
GB0226434D0 (en) Combination product
DK1079843T3 (da) Anvendelse af a1beta1 integrinreceptorinhibitorer og TFG beta1 inhibitorer til behandling af nyresygdom
DK0991424T3 (da) Farmaceutiske præparater omfattende en inhibitor for aldosereduktase og en inhibitor for ACE
RS51534B (en) NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT
ATE354291T1 (de) Zusammensetzungen enthaltend mindestens kürbisöl und borretschöl, deren verwendung als arzneimittel, dermatikum oder dermatokosmetische zusammensetzung
MXPA03001455A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa.
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
DK1135169T3 (da) Anvendelse af et farmaceutisk præparat indeholdende et anticancermiddel og mindst et peptid.
AR046853A1 (es) Mezclas insecticidas que contienen triflumuron con actividad sinergica
UY26618A1 (es) Composiciones farmacéuticas de inhibidores de la gcomposiciones farmacéuticas de inhibidores de la glucógeno-fosforilasa
ATE392644T1 (de) Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
AR031404A1 (es) Una composicion y metodo de aplicacion
HK1077008A1 (en) Composition for treating hemorrhoids

Legal Events

Date Code Title Description
FA Abandonment or withdrawal